AMENDMENT TO CLAIMS

The listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claim 1 (cancelled).

Claim 2 (cancelled).

Claim 3 (cancelled).

Claim 4 (canceled).

Claim 5 (cancelled).

Claim 6 (cancelled).

Claim 7 (cancelled.

Claim 8 (cancelled).

Claim 9 (cancelled).

Claim 10 (cancelled).

Claim 11 (previously canceled).

Claim 12 (previously canceled).

Claim 13 (currently amended): A method of treating <u>airway and</u> <u>gastrointestinal disorders</u> <u>inflammation</u>, <u>allergy</u>, <u>nasal congestion</u>, <u>diseases of the GI tract</u>, <u>cardiovascular disease</u>, <u>or disturbances of the central nervous system as well as allergy induced airway responses</u>, and <u>obesity</u>, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 4 <u>16</u>.

Claim 14 (previously cancelled).

Claim 15 (currently amended): A method of preparing a pharmaceutical composition for treating <u>airway and gastrointestinal disorders</u> inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy induced airway responses, and obesity, said method comprising bringing into intimate contact a compound of claim 4 <u>16</u> and a pharmaceutically acceptable carrier.

Claim 16 (previously amended): A compound exhibiting H₃ antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:

<u>Claim 17 (previously amended)</u>: A compound exhibiting both H₁ and H₃ antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:

Claim 18 (currently amended): A pharmaceutical composition for treating airway and gastrointestinal disorders inflammation, allergy, nasal congestion, diseases of the GI-tract, cardiovascular disease, or disturbances of the central nervous system as well as allergy-induced airway responses, and obesity, said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.

Claims 19-21 (cancelled).

Claim 22 (new claim): A method of treating airway and gastrointestinal disorders, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 17.

Claim 23 (new claim): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders, said method comprising bringing into intimate contact a compound of claim 17 and a pharmaceutically acceptable carrier.